OncologyOnline.net

Oncology Xagena

Xagena Mappa
Medical Meeting
Dermabase.it
Gastrobase.it

Search results for "Opdivo"

The results from CheckMate -037, a phase 3 randomized, controlled open-label study of Nivolumab ( Opdivo ), an investigational PD-1 immune checkpoint inhibitor, versus investigator’s choice chemothera ...


Nivolumab ( Opdivo ) is a fully human immunoglobulin G4 programmed death-1 immune checkpoint inhibitor antibody that restores T-cell immune activity. A phase II trial assessed the antitumor activity ...


Nivolumab ( Opdivo ) is a fully human immunoglobulin G4 programmed death-1 immune checkpoint inhibitor antibody that restores T-cell immune activity. A phase II trial has assessed the antitumor acti ...


The FDA ( Food and Drug Administration ) has expanded the approved use of Opdivo ( Nivolumab ) to treat patients with advanced ( metastatic ) squamous non-small cell lung cancer ( NSCLC ) with progres ...


Results from CheckMate -025, a phase 3 study comparing Nivolumab ( Opdivo ) to Everolimus ( Afinitor ) in advanced renal cell carcinoma ( RCC ) after prior anti-angiogenic treatment, showed a signific ...


Longer term ( 18 month ) survival data from CheckMate -057, an open-label, randomized phase 3 study evaluating Nivolumab [ Opdivo ] ( n=292 ) versus Docetaxel [ Taxotere ] ( n=290 ) in previously trea ...


Treatment with programmed death receptor-1 ( PD-1 ) antibodies is associated with high response rates in patients with advanced melanoma. Reliable markers for early response and outcome are still spar ...


The advent of new immunotherapies for the treatment of metastatic melanoma has resulted in various novel combination strategies. Because of their distinct modes of action, different immunotherapies ha ...


Two-year overall survival data from two pivotal phase 3 studies evaluating Nivolumab ( Opdivo ) versus Docetaxel in previously treated metastatic non-small cell lung cancer ( NSCLC ) were announced. ...


The baseline serum cytokine levels of Platinum pretreated patients with advanced squamous non-small cell lung cancer ( NSCLC ) altered the efficacy of immunotherapy with Nivolumab ( Opdivo ), a fully ...


Interim data from the phase 2 CheckMate -142 trial evaluating Nivolumab ( Opdivo ) alone or in combination with Ipilimumab ( Yervoy ) in patients with previously treated metastatic colorectal cancer, ...


The results for Nivolumab ( Opdivo ) in the cohort of patients with metastatic urothelial cancer ( n=78 ), the most common type of bladder cancer, after Platinum-based therapy from CheckMate -032, a p ...


Nivolumab ( Opdivo ) maintains function and reduces symptoms in treatment of relapsed metastatic head and neck cancer, according to results from the CheckMate 141 trial presented at the ESMO 2016 Cong ...


New patient-reported quality-of-life data from an exploratory endpoint in the pivotal phase 3 CheckMate -141 trial evaluating Nivolumab ( Opdivo ) in patients with recurrent or metastatic squamous cel ...


Results from the phase 3 CheckMate -214 trial evaluating Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ) versus Sunitinib ( Sutent ) in patients with previously untreated advanced or metastatic renal ...